GHK-Cu for Hair Research: Dermal Papilla Activation and the Anagen Phase

Among the copper peptides studied in skin and follicle biology, GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) sits at the center of the GHK-Cu hair growth research conversation. First isolated by Loren Pickart in the 1970s, this naturally occurring tripeptide-copper complex has been investigated in cell culture, ex vivo human tissue, and small clinical studies for its effects on the dermal papilla cells that orchestrate the hair cycle. This article surveys the preclinical and human literature on how GHK-Cu has been studied in relation to dermal papilla activation and the anagen (growth) phase. Everything below describes laboratory and research-context findings only. The compounds discussed are sold strictly for research use only and are not for human consumption.

GHK-Cu and Hair-Follicle Research

GHK-Cu is one of the most extensively characterized copper-binding peptides in dermatologic research. Across reviews of its biology, the peptide is described as a delivery vehicle for bioavailable copper and as a modulator of tissue-remodeling and regenerative gene expression. A widely cited 2015 review in the *International Journal of Molecular Sciences* catalogs GHK as a signal that influences collagen and glycosaminoglycan synthesis, antioxidant pathways, and inflammatory signaling, framing it as a multi-pathway modulator rather than a single-target molecule. That same remodeling and growth-factor biology is what drew researchers to ask whether the peptide also influences the hair follicle, an organ that depends on coordinated cell proliferation, vascular support, and matrix turnover during each growth cycle.

Dermal Papilla Cell Activation

The dermal papilla is a cluster of specialized mesenchymal cells at the base of the hair follicle that signals the surrounding epithelial cells and effectively sets the pace of the hair cycle. Because dermal papilla cell number and activity track with follicle size and growth duration, these cells are a primary readout in follicle research. GHK-Cu and the closely related copper tripeptide AHK-Cu have been studied for their ability to act on this population.

In a frequently referenced 2007 in vitro and ex vivo study published in *Archives of Pharmacal Research* (Pyo et al.), the copper tripeptide AHK-Cu stimulated elongation of cultured human hair follicles and promoted proliferation of dermal papilla cells at picomolar-to-nanomolar concentrations, while also reducing the number of apoptotic (dying) dermal papilla cells. The authors proposed that the peptide supports follicle growth specifically by stimulating dermal papilla cell proliferation and limiting their apoptosis — a mechanism that established the dermal papilla as the central cellular target in copper-peptide follicle research.

The Hair Cycle: Anagen, Catagen, Telogen

Every follicle cycles through three phases:

• Anagen — the active growth phase, during which the dermal papilla drives matrix-cell proliferation and the hair shaft lengthens. Longer anagen generally means longer, fuller hair.
• Catagen — a short regression phase in which the lower follicle involutes and growth halts.
• Telogen — the resting phase, after which the old hair is shed and a new anagen cycle ideally begins.

Most research interest in copper peptides centers on supporting or extending the anagen phase and on encouraging follicles to re-enter anagen from rest. In the preclinical literature, copper-peptide exposure has been associated with faster anagen entry and prolonged follicle elongation in culture — outcomes consistent with the dermal papilla proliferation effects described above. These are tissue-model and animal-model observations, and the distinction between cell-culture, ex vivo human tissue, and live-animal evidence matters when interpreting them.

Human Study Hooks and Reported Counts

The most cited human data point comes from a 2016 randomized, double-blind, placebo-controlled study published in *Annals of Dermatology* (Lee et al., PMID 27489425). The trial tested a topical complex of the GHK peptide combined with 5-aminolevulinic acid (5-ALA) in 45 men with pattern hair loss over six months, comparing two active concentrations against placebo.

Two honest caveats accompany this often-quoted figure. First, the active agent was a GHK-plus-5-ALA complex, not GHK-Cu in isolation, so the copper-peptide contribution cannot be cleanly separated from the 5-ALA component. Second, the sample was small and single-center. As broader reviews note, large multi-center randomized trials of copper peptides for hair are still lacking, and the evidence base does not match that behind established hair-loss agents. The +71.5 vs +9.6 contrast is a real, statistically significant signal worth studying — not a demonstration of efficacy for any human use.

Mechanistic Pathways: Growth Factors and Follicle Signaling

The proposed mechanisms tie the cellular and tissue observations together through follicle growth-factor signaling and an improved follicle environment:

• VEGF (vascular endothelial growth factor): the 2007 copper-tripeptide work reported elevated VEGF production from dermal fibroblasts, consistent with enhanced perifollicular vascular support — a recognized correlate of robust anagen.
• TGF-β1 modulation: the same study reported decreased secretion of transforming growth factor-β1, a signal associated with catagen induction; reducing it is consistent with prolonging the growth phase.
• Wnt/β-catenin signaling: nuclear β-catenin accumulation in dermal papilla cells is a canonical trigger for anagen entry, and copper peptides have been studied in the context of this pathway in animal models.
• Copper delivery and remodeling: as a bioavailable copper carrier, GHK-Cu is studied for supporting extracellular-matrix remodeling and antioxidant balance in the dermal compartment surrounding the follicle.

Taken together, the literature frames the GHK-Cu mechanism as activation of dermal papilla cells coupled with a more growth-supportive follicle microenvironment — increased angiogenic signaling, reduced pro-catagen signaling, and remodeling support — rather than a single direct hormonal action.

GHK-Cu in Glow and Klow Formulations

In our research catalog, GHK-Cu appears as a standalone copper-peptide SKU and as a component of two blended research formulations. The standalone GHK-Cu listing supports work focused specifically on copper-tripeptide biology, while Glow and Klow are multi-component research blends that incorporate GHK-Cu alongside other peptides for studies examining combined signaling. Researchers comparing single-peptide versus blended exposures can browse all three on the products page. As with every item we carry, each lot is third-party HPLC tested, and the corresponding certificate of analysis can be checked on our verification page.

Research-Use-Only Considerations

The GHK-Cu hair literature is promising but early: foundational mechanism work in cell culture and ex vivo human tissue, supportive animal-model data, and one small human study of a GHK-plus-5-ALA complex. None of this establishes a therapeutic claim, and nothing here should be read as administration guidance for people.

For related background, see our other research write-ups in the learning library, and review COA and lot documentation on the verify page before designing any in vitro or preclinical study.